Lupin Receives Approval for Albendazole Tablets USP

Pharma major Lupin Limited (Lupin) announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Albenza® Tablets, 200 mg, of Impax Laboratories Inc.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:

- Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm

- Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm

Albendazole Tablets USP (RLD: Albenza®) had an annual sales of approximately USD 34 million in the U.S. (IQVIA MAT April 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.920.45 as compared to the previous close of Rs. 928.6. The total number of shares traded during the day was 67246 in over 2711 trades.

The stock hit an intraday high of Rs. 931.55 and intraday low of 912.5. The net turnover during the day was Rs. 61931647.

Source : Equity Bulls

Keywords